St Jude's Epiducer now global with US clearance; gets go-ahead for BROADENing DBS study
This article was originally published in Clinica
Executive Summary
St Jude Medical has received the green light to market its Epiducer neurostimulation lead delivery system in the US. The 510(k) clearance from the FDA comes over a year after the system was CE marked; it is now currently St Jude's best-selling neurostimulation lead delivery system in Europe, the firm had told Clinica at the annual International Neuromodulation Society meeting in London earlier this year (www.clinica.co.uk, 25 May 2011).
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.